Excessive pricing and orphan drugs: Leadiant sanctioned by the Italian Antitrust Authority
Related people
Headlines in this article
Related news and insights
Blog Post: 03 April 2024
European Commission opens unprecedented abuse of dominance probe in animal medicines sector
Publications: 02 April 2024
Blog Post: 28 March 2024
Publications: 14 March 2024
Infringing gin part II: Court of Appeal victory for M&S against Aldi’s copycat design
The Italian Antitrust Authority has recently decided that Leadiant infringed Article 102 TFEU through a multifaceted strategy that led to it obtaining an excessive price for its CDCA Leadiant® medicine.
Our alert analyses key aspects of the IAA’s decision and draws out key takeaways for pharmaceutical companies operating in the EU.